Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

MediPal Holdings Yönetim

Yönetim kriter kontrolleri 2/4

MediPal Holdings' CEO'su Shuichi Watanabe, Apr2012 tarihinde atandı, in görev süresi 12.5 yıldır. şirketin hisselerinin 0.084% doğrudan sahiptir ve bu hisselerin değeri ¥ 444.13M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 9.8 yıl ve 6.8 yıldır.

Anahtar bilgiler

Shuichi Watanabe

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	12.5yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	9.8yrs
Yönetim Kurulu ortalama görev süresi	6.8yrs

Son yönetim güncellemeleri

Recent updates

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 05

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

Jun 25

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

May 22

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

May 08

CEO

Shuichi Watanabe (72 yo)

12.5yrs

Görev süresi

Mr. Shuichi Watanabe has been Chief Compliance Officer of MediPal Holdings Corporation since June 25, 2020. Mr. Watanabe has been Chief Executive Officer and President at MediPal Holdings Corporation since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shuichi Watanabe	Chief Compliance Officer	12.5yrs	Veri yok	0.084% ¥ 453.4m
Yuji Sakon	MD, GM of Administration Division & Director	11.3yrs	Veri yok	0.011% ¥ 59.6m
Toshihide Yoda	Senior MD of Investor Relations	1.3yrs	Veri yok	0.0063% ¥ 33.7m
Yasuhiro Choufuku	Executive VP & Director	8.3yrs	Veri yok	0.025% ¥ 134.8m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	no data	Veri yok	0.017% ¥ 93.3m

9.8yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim: 7459 'un yönetim ekibi deneyimli ve deneyimlidir ( 9.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Shuichi Watanabe	Chief Compliance Officer	24.8yrs	Veri yok	0.084% ¥ 453.4m
Yuji Sakon	MD, GM of Administration Division & Director	12.3yrs	Veri yok	0.011% ¥ 59.6m
Toshihide Yoda	Senior MD of Investor Relations	14.3yrs	Veri yok	0.0063% ¥ 33.7m
Yasuhiro Choufuku	Executive VP & Director	5.3yrs	Veri yok	0.025% ¥ 134.8m
Shinjiro Watanabe	GM of Information Systems Management Division & Director	11.3yrs	Veri yok	0.017% ¥ 93.3m
Kuniko Shoji	Independent Outside Director	6.3yrs	Veri yok	Veri yok
Toshio Asano	Independent Outside Director	7.3yrs	Veri yok	0.0034% ¥ 18.2m
Hiroshi Iwamoto	Independent Outside Director	3.3yrs	Veri yok	Veri yok
Koichi Mimura	Director	4.3yrs	Veri yok	0.00096% ¥ 5.2m
Mitsuko Kagami	Independent Outside Director	10.3yrs	Veri yok	Veri yok
Takuya Yoshida	Director	1.3yrs	Veri yok	0.00048% ¥ 2.6m
Seiichi Kasutani	Director	5.8yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7459 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

MediPal Holdings Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Recent updates

Upcoming dividend of JP¥30.00 per share

MediPal Holdings (TSE:7459) Will Pay A Dividend Of ¥30.00

MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024

Calculating The Fair Value Of MediPal Holdings Corporation (TSE:7459)

MediPal Holdings (TSE:7459) Has Announced A Dividend Of ¥30.00

Dividend of JP¥30.00 announced

Now 27% undervalued after recent price drop

MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2025 earnings released: EPS: JP¥42.95 (vs JP¥52.32 in 1Q 2024)

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB

Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes

MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024

MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744).

Concerns Surrounding MediPal Holdings' (TSE:7459) Performance

Full year 2024 earnings: EPS exceeds analyst expectations

MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024

MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million.

Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E

MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion.

Upcoming dividend of JP¥30.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023)

MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024

Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023)

Price target increased by 9.5% to JP¥2,475

Upcoming dividend of JP¥30.00 per share at 2.3% yield

MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023

First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023)

Price target increased by 12% to JP¥2,198

MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 14%

MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥23.00 per share at 2.6% yield

Now 22% undervalued

Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022)

MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506).

MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022)

Upcoming dividend of JP¥23.00 per share

MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022

First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022)

MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorated over the past week

MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022

Less than half of directors are independent

Upcoming dividend of JP¥21.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 20% undervalued

Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021)

Upcoming dividend of JP¥21.00 per share

First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020)

Upcoming dividend of JP¥21.00 per share

MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021

Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020)

Revenue and earnings beat expectations

New 90-day high: JP¥2,141

Analysts update estimates

Analysts update estimates

MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021

MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020

MediPal Holdings Corporation to Report Q1, 2021 Results on Jul 31, 2020

CEO

Görev süresi

Liderlik Ekibi